Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2026 · third_quarter · Q3
Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2026 · second_quarter · Q2
Source: Senate LDA
Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2026 · first_quarter · Q1
Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2025 · fourth_quarter · Q4
Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2025 · third_quarter · Q3
Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2025 · second_quarter · Q2
Lack of innovation in mental health, need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2025 · first_quarter · Q1
Mental Health, FDA/DEA communication on controlled substances, VA funding for operational infrastructure for mental health care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
2025 · first_quarter · RR
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs
Health Care, Mental Health, Brain Health, Medicare/Medicaid, VA, Tariffs